within Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G02C_OtherGynecologicals.G02CX05_Bremelanotide;

model Bremelanotide
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 4.972222222222223e-07,
    adminDuration = 600,
    adminMass = 1.75 / 1000000,
    adminCount = 1,
    Vd = 0.0253,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Bremelanotide</td></tr><tr><td>ATC code:</td><td>G02CX05</td></tr><td>route:</td><td>subcutaneous</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>1.75</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>25.3</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1.79</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Bremelanotide is a melanocortin receptor agonist used for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. It is administered subcutaneously and is currently approved for this indication in the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy premenopausal women after a single subcutaneous dose.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.G.G02CX05 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Bremelanotide;
